- PCI Pharma Services is investing over $365 million in new and expanded facilities for drug-device combination packaging.
- The expansion focuses on injectable drug formats and includes projects in both the U.S. and Europe.
PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has announced plans to invest over $365 million in new and expanded facilities to support the packaging of drug-device combination products. The expansion focuses on advanced drug delivery systems, particularly injectable formats, and is part of PCI’s broader strategy to enhance its global infrastructure.
The initiative includes the development of new facilities in Europe and North America, with the company’s Biotech Center of Excellence in Philadelphia already benefiting from upgraded capabilities in prefilled syringes and autoinjector assembly. These investments will enable PCI to manage the entire lifecycle of drug-device products, from development and clinical trials through to commercial-scale production.
In the U.S., PCI is planning a 545,000-square-foot expansion at its Rockford, Illinois campus. This site will house over 20 customer suites and will support scalable technology for packaging injectable products, including vials, syringes, autoinjectors, and pen-cartridge combinations. The facility will include sophisticated assembly and testing equipment to ensure compliance with ISO standards, with operations expected to begin in the third quarter of 2025.
“We’re expanding our capabilities to support the growing demand for complex drug delivery systems,” said Justin Schroeder, Senior Executive Director, Global Marketing & Design at PCI. “Our investment in new technologies and facilities reflects our commitment to meeting the needs of our customers.”
Overview of outsourcing trends 
